SETD2 and non-small cell lung carcinoma: Significantly more common co-occurring gene alterations among RET fusion-positive vs negative NSCLC patients include CDKN2B, SETD2, MDM2, SMAD4, FRS2, and ARFRP1 (P < 0.05).